Physician profile
Jun Ma
NPI 1215563812
$6,162.73
in general payments reported to CMS, 2019-2025
47 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $1,033 · 2023: $2,218 · 2024: $1,567 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Education: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.90 |
| Education | $1,067.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,308.11 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Merck Sharp & Dohme LLC | $475.93 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $456.26 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $317.68 | 2022-2025 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $216.38 | 2023-2025 | Calquence, Enhertu |
| Astellas Pharma US INC | $213.25 | 2023 | |
| Lilly USA, LLC | $208.55 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Novartis Pharmaceuticals Corporation | $196.21 | 2022-2025 | |
| Daiichi Sankyo INC. | $186.76 | 2022-2025 | Enhertu, Datroway |
| Genzyme Corporation | $174.42 | 2022-2025 | |
| Pfizer INC. | $164.03 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.60 | 2023-2025 | Ninlaro, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $137.45 | 2022-2023 | Imbruvica |
| Exelixis INC. | $121.20 | 2023 | Cabometyx |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.